Fonville JM., Wilks SH., James SL., Fox A., Ventresca M., Aban M., Xue L., Jones TC., Le N. M. H. None., Pham Q. T. None., Tran N. D. None., Wong Y., Mosterin A., Katzelnick LC., Labonte D., Le T. T. None., van der Net G., Skepner E., Russell CA., Kaplan TD., Rimmelzwaan GF., Masurel N., de Jong JC., Palache A., Beyer WEP., Le Q. M. None., Nguyen T. H. None., Wertheim HFL., Hurt AC., Osterhaus ADME., Barr IG., Fouchier RAM., Horby PW., Smith DJ.

We introduce the antibody landscape, a method for the quantitative analysis of antibody-mediated immunity to antigenically variable pathogens, achieved by accounting for antigenic variation among pathogen strains. We generated antibody landscapes to study immune profiles covering 43 years of influenza A/H3N2 virus evolution for 69 individuals monitored for infection over 6 years and for 225 individuals pre- and postvaccination. Upon infection and vaccination, titers increased broadly, including previously encountered viruses far beyond the extent of cross-reactivity observed after a primary infection. We explored implications for vaccination and found that the use of an antigenically advanced virus had the dual benefit of inducing antibodies against both advanced and previous antigenic clusters. These results indicate that preemptive vaccine updates may improve influenza vaccine efficacy in previously exposed individuals.

Antibody landscapes after influenza virus infection or vaccination

DOI

Type

Journal

Publisher

Publication Date

Volume

Pages